RenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. Our lead product candidate, RenovoGem, is a combination of gemcitabine and our patented delivery system regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). Targeted therapy via RenovoTAMP platform safely and without transmission to non-targeted areas, is our primary focus. RenovoRx’s patent portfolio currently includes seven issued US patents and one European patent for ourtechnology with several additional patents pending in the US, Europe, and Asia. After demonstrating a median survival of 27.9 months in Phase 1/2 clinical trials vs. 12-15 months reported in historical studies for this patient population, RenovoRx secured two separate Orphan Drug Designations from the FDA for intra-arterial gemcitabine: pancreatic cancer and bile duct cancer (cholangiocarcinoma). This therapy is being further studied in the currently enrolling Phase 3 TIGeR-PaC clinical trial in pancreatic cancer and has a primary endpoint of overall survival and several secondary endpoints, including quality of life. The Phase 3 TIGeR-PaC clinical trial is enrolling unresectable locally advanced pancreatic cancer patients (LAPC) in the United States.
View Top Employees from RenovoRxWebsite | http://www.renovorx.com |
Ticker | RNXT |
Revenue | $7 million |
Employees | 15 (9 on RocketReach) |
Founded | 2009 |
Address | 4546 El Camino Real B1, Los Altos, California 94022, US |
Phone | (650) 424-0818 |
Fax | (650) 397-4433 |
Technologies |
JavaScript,
HTML,
PHP
+21 more
(view full list)
|
Industry | Biotechnology Research, Medical Devices & Equipment, Health Care, Manufacturing, Medical Device, Therapeutics |
Web Rank | 17 Million |
Keywords | Renovorx Clinical Trials, Renovo Rx |
Competitors | Atc Technologies Inc, Bacchus Vascular, Biomerix Corporation, CeQur, Promaxo |
SIC | SIC Code 384 Companies, SIC Code 38 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular RenovoRx employee's phone or email?
The RenovoRx annual revenue was $7 million in 2024.
Angela Nelms is the COO of RenovoRx.
9 people are employed at RenovoRx.
RenovoRx is based in Los Altos, California.
The NAICS codes for RenovoRx are [33, 541, 54].
The SIC codes for RenovoRx are [384, 38].